On the list I talked about, the seven drugs that were looked at as first-in-class drugs, one of the drugs on there is our own Sensipar. The product is used for people on dialysis, a very serious disease. Today, after a negative CDR recommendation, it is approved in Quebec for reimbursement, and it is actually under certain conditions approved in B.C. for reimbursement.
The irony of this is that this drug is manufactured in Canada for the world, and Canadian patients don't have access to it. It doesn't make sense. It just doesn't make sense. This product is available in France, in Europe in every country, but most provinces in Canada, except for Quebec and B.C., say no to these drugs based on a negative CDR recommendation. It does not do the patient justice.